Galera Therapeutics (NASDAQ:GRTX) shares are trading higher after the company announced updated data from its randomized, multicenter, placebo-controlled trial in patients with pancreatic cancer.
"The data from this trial continue to impress, showing consistent and durable benefits across multiple measures, including the most important for the patient, overall survival," said Mel Sorensen, M.D., President and CEO of Galera.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Galera Therapeutics Inc is a biopharmaceutical company focused on developing therapeutics that have the potential to transform radiotherapy in cancer.
The stock was trading 23.45% higher at $8.16. The stock has a 52-week high of $15 and a 52-week low of $6.15.